Onali, Sebastiano
 Distribuzione geografica
Continente #
NA - Nord America 158
EU - Europa 125
AS - Asia 44
AF - Africa 1
Totale 328
Nazione #
US - Stati Uniti d'America 157
SE - Svezia 44
IT - Italia 42
SG - Singapore 18
CN - Cina 14
IE - Irlanda 12
ID - Indonesia 9
DE - Germania 8
FR - Francia 7
AT - Austria 4
CZ - Repubblica Ceca 3
HK - Hong Kong 2
RU - Federazione Russa 2
CI - Costa d'Avorio 1
FI - Finlandia 1
IR - Iran 1
MX - Messico 1
NL - Olanda 1
PL - Polonia 1
Totale 328
Città #
Chandler 50
Ashburn 15
Singapore 15
New York 14
Milan 13
Dublin 12
Jakarta 9
Cagliari 7
Rome 7
Marseille 6
Princeton 6
Boston 5
Guasila 4
Los Angeles 4
Vienna 4
Shenyang 3
Bremen 2
Brno 2
Hong Kong 2
Moscow 2
Munich 2
Pavia 2
Portocannone 2
San Mateo 2
Seattle 2
Abidjan 1
Boydton 1
Brdo 1
Castellammare del Golfo 1
Charlotte 1
Corigliano d'Otranto 1
Duncan 1
Hanover 1
Houston 1
Kashan 1
Krimpen Aan Den Ijssel 1
Lappeenranta 1
Leawood 1
Miami 1
North Charleston 1
Paris 1
Sacramento 1
Stockholm 1
Taranto 1
Warsaw 1
Washington 1
Wilmington 1
Totale 214
Nome #
Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy 57
Drug-Related Pneumonitis in Patients Receiving Vedolizumab Therapy for Inflammatory Bowel Disease 52
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre 51
Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy 46
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients 40
Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study 37
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients 32
Combined Salivary Proteome Profiling and Machine Learning Analysis Provides Insight into Molecular Signature for Autoimmune Liver Diseases Classification 14
Top-Down Proteomics Detection of Potential Salivary Biomarkers for Autoimmune Liver Diseases Classification 9
Totale 338
Categoria #
all - tutte 2.131
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.131


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202242 0 0 0 0 0 0 0 0 0 0 22 20
2022/2023152 20 21 10 20 9 15 8 14 26 1 5 3
2023/2024111 3 27 2 8 9 20 7 8 1 4 9 13
2024/202533 4 3 23 3 0 0 0 0 0 0 0 0
Totale 338